Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?

Salim Can^{1

2

3}, Melek Yorgun Altunbas^{1

2

3}, Ahmet Ozen^{1

2

3}

Affiliations

¹ Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.
² Istanbul Jeffrey Modell Diagnostic Center for Primary Immunodeficiency Diseases, Istanbul, Turkey.
³ The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.

Editorial

Salim Can et al. Expert Opin Pharmacother. 2024 Aug.

. 2024 Aug;25(11):1421-1426.

doi: 10.1080/14656566.2024.2388267. Epub 2024 Aug 4.

Salim Can^{1

2

3}, Melek Yorgun Altunbas^{1

2

3}, Ahmet Ozen^{1

2

3}

¹ Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.
² Istanbul Jeffrey Modell Diagnostic Center for Primary Immunodeficiency Diseases, Istanbul, Turkey.
³ The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.

No abstract available

Keywords: CD55; CHAPLE disease; eculizumab; pozelimab; primary intestinal lymphangiectasia; protein-losing enteropathy.

Publication types